PMID- 36340433
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221108
IS  - 2423-3439 (Print)
IS  - 2423-3420 (Electronic)
IS  - 2423-3420 (Linking)
VI  - 8
IP  - 1
DP  - 2022 Mar
TI  - Antifungal activity of Taurolidine against Mucorales: An in vitro study on 
      clinical isolates.
PG  - 26-31
LID - 10.18502/cmm.8.1.9211 [doi]
AB  - BACKGROUND AND PURPOSE: Taurolidine is active against a wide variety of 
      micro-organisms, including bacteria and fungi. Mucormycosis is one of the 
      life-threatening opportunistic fungal infections, especially in immunocompromised 
      patients. Currently, the emergence of Mucormycosis during the COVID-19 pandemic 
      raises public health concerns regarding untoward morbidity and mortality among 
      SARS-CoV-2 patients. It is well-known that delayed and inappropriate antifungal 
      therapy leads to increased morbidity and mortality. This study aimed to 
      investigate the in-vitro antifungal activity of taurolidine to evaluate its 
      effects against clinical isolates of Mucorales. MATERIALS AND METHODS: This study 
      included previously collected clinical Mucorales isolates. The minimum in vitro 
      inhibitory concentration (MIC) of amphotericin B, caspofungin, voriconazole, 
      posaconazole, and itraconazole was determined using the broth microdilution 
      method. RESULTS: All clinical isolates showed full sensitivity to amphotericin B. 
      Posaconazole MIC range from 8 mug/mL to 0.032‎ mug/mL. The MIC range of 
      voriconazole and caspofungin were determined to be 2-8 microg/mL and 0.5-16 microg/mL, 
      respectively. Growth of the isolates was entirely inhibited in 1000 microg/mL 
      concentration of taurolidine. In microscopic observations, morphological effects 
      on hyphal growth were observed at 500 microg/mL concentration. CONCLUSION: In 
      conclusion, this is an updated experience of using taurolidine against Mucorales. 
      However, our in-vitro findings need to be confirmed in well-designed clinical 
      trials aimed at treating invasive Mucormycosis infections.
CI  - Copyright: (c) 2021, Published by Mazandaran University of Medical Sciences on 
      behalf of Iranian Society of Medical Mycology and Invasive Fungi Research Center.
FAU - Jafarian, Hadis
AU  - Jafarian H
AD  - Clinical Microbiology Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Amanati, Ali
AU  - Amanati A
AD  - Alborzi Clinical Microbiology Research Center, Shiraz University of Medical 
      Sciences, Shiraz, Iran.
AD  - Department of Pediatrics, Division of Pediatric Infectious Diseases, School of 
      Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Badiee, Parisa
AU  - Badiee P
AD  - Clinical Microbiology Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Curr Med Mycol
JT  - Current medical mycology
JID - 101647935
PMC - PMC9548082
OTO - NOTNLM
OT  - Minimum inhibitory concentrations
OT  - Mucormycosis
OT  - Taurolidine
OT  - Mucorales
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have influenced the work reported in any way.
EDAT- 2022/11/08 06:00
MHDA- 2022/11/08 06:01
PMCR- 2022/03/01
CRDT- 2022/11/07 05:01
PHST- 2021/10/30 00:00 [received]
PHST- 2022/01/25 00:00 [revised]
PHST- 2022/03/19 00:00 [accepted]
PHST- 2022/11/07 05:01 [entrez]
PHST- 2022/11/08 06:00 [pubmed]
PHST- 2022/11/08 06:01 [medline]
PHST- 2022/03/01 00:00 [pmc-release]
AID - CMM-8-1 [pii]
AID - 10.18502/cmm.8.1.9211 [doi]
PST - ppublish
SO  - Curr Med Mycol. 2022 Mar;8(1):26-31. doi: 10.18502/cmm.8.1.9211.